as 11-15-2024 4:00pm EST
GeneDx Holdings Corp delivers personalized and actionable health insights to inform diagnosis, direct treatment and improve drug discovery. The company is uniquely positioned to accelerate the use of genomic and large-scale clinical information to enable precision medicine as the standard of care. GeneDx is at the forefront of transforming healthcare through its various exome and genome testing and interpretation, fueled by one of the world's substantial rare disease data sets. It has two segments GeneDx, which derives maximum revenue and Legacy Sema4 diagnostics.
Founded: | N/A | Country: | United States |
Employees: | 1000 | City: | N/A |
Market Cap: | N/A | IPO Year: | 2020 |
Target Price: | N/A | AVG Volume (30 days): | N/A |
Analyst Decision: | N/A | Number of Analysts: | N/A |
Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
EPS: | N/A | EPS Growth: | N/A |
52 Week Low/High: | N/A | Next Earning Date: | N/A |
Revenue: | N/A | Revenue Growth: | N/A |
Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
WGSWW Breaking Stock News: Dive into WGSWW Ticker-Specific Updates for Smart Investing
Motley Fool
a day ago
Barrons.com
2 days ago
Barrons.com
9 days ago
Business Wire
10 days ago
Zacks
11 days ago
Zacks
12 days ago
Business Wire
13 days ago
Zacks
13 days ago
The information presented on this page, "WGSWW GeneDx Holdings Corp. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.